$23.08
00.00%
Pre-Market: Jul 19, 5:07 PM EDT
15 minutes delayed
Comments
Loading...
Syndax Pharmaceuticals
SNDXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock, Analyst Ratings, Price Targets, Forecasts
Syndax Pharmaceuticals Inc has a consensus price target of $34.2 based on the ratings of 15 analysts. The high is $45 issued by Mizuho on December 22, 2023. The low is $21 issued by Morgan Stanley on October 12, 2021. The 3 most-recent analyst ratings were released by Jefferies, Stifel, and HC Wainwright & Co. on June 28, 2024, June 26, 2024, and June 17, 2024, respectively. With an average price target of $40 between Jefferies, Stifel, and HC Wainwright & Co., there's an implied 73.31% upside for Syndax Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Stifel
HC Wainwright & Co.
JP Morgan
Citigroup
1calculated from analyst ratings
Analyst Ratings for Syndax Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 60.31% | Jefferies | Kelly Shi | → $37 | Initiates | → Buy | Get Alert |
| 06/26/2024 | Buy Now | 81.98% | Stifel | Bradley Canino | $40 → $42 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | $41 → $41 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | $41 → $41 | Reiterates | Buy → Buy | Get Alert |
| 05/21/2024 | Buy Now | 47.31% | JP Morgan | Anupam Rama | $34 → $34 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 29.98% | Citigroup | Yigal Nochomovitz | $32 → $30 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 73.31% | Stifel | Bradley Canino | $39 → $40 | Maintains | Buy | Get Alert |
| 04/26/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | — | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | $41 → $41 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 47.31% | JP Morgan | Anupam Rama | $31 → $34 | Maintains | Overweight | Get Alert |
| 02/28/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | -0.35% | Scotiabank | George Farmer | $36 → $23 | Downgrade | Sector Outperform → Sector Perform | Get Alert |
| 01/02/2024 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 12/22/2023 | Buy Now | 77.64% | HC Wainwright & Co. | Edward White | $42 → $41 | Maintains | Buy | Get Alert |
| 12/22/2023 | Buy Now | 94.97% | Mizuho | Mara Goldstein | → $45 | Initiates | → Buy | Get Alert |
| 10/26/2023 | Buy Now | 55.98% | Stifel | Bradley Canino | $38 → $36 | Maintains | Buy | Get Alert |
| 10/25/2023 | Buy Now | 25.65% | B of A Securities | Jason Zemansky | → $29 | Initiates | → Buy | Get Alert |
| 10/17/2023 | Buy Now | 64.64% | JP Morgan | Anupam Rama | $36 → $38 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | 29.98% | Goldman Sachs | Chris Shibutani | → $30 | Initiates | → Buy | Get Alert |
| 10/02/2023 | Buy Now | 81.98% | HC Wainwright & Co. | Edward White | $38 → $42 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | 42.98% | JP Morgan | Anupam Rama | $36 → $33 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 64.64% | HC Wainwright & Co. | Edward White | → $38 | Reiterates | → Buy | Get Alert |
| 07/27/2023 | Buy Now | 68.98% | Scotiabank | George Farmer | → $39 | Initiates | → Sector Outperform | Get Alert |
| 07/26/2023 | Buy Now | 51.65% | Citigroup | Yigal Nochomovitz | $31 → $35 | Maintains | Buy | Get Alert |
| 07/26/2023 | Buy Now | 47.31% | Barclays | Peter Lawson | $31 → $34 | Maintains | Overweight | Get Alert |
| 07/25/2023 | Buy Now | 81.98% | Guggenheim | Michael Schmidt | $40 → $42 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 55.98% | B. Riley Securities | Kalpit Patel | $34 → $36 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 64.64% | HC Wainwright & Co. | Edward White | $36 → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 73.31% | Guggenheim | Michael Schmidt | → $40 | Initiates | → Buy | Get Alert |
| 06/26/2023 | Buy Now | 51.65% | BTIG | Justin Zelin | $34 → $35 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 34.32% | Citigroup | Yigal Nochomovitz | $32 → $31 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 55.98% | HC Wainwright & Co. | Edward White | $33 → $36 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 55.98% | JP Morgan | Anupam Rama | $41 → $36 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 38.65% | Citigroup | Yigal Nochomovitz | $29 → $32 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 47.31% | Goldman Sachs | Madhu Kumar | $39 → $34 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 42.98% | HC Wainwright & Co. | Edward White | → $33 | Reiterates | → Buy | Get Alert |
| 01/31/2023 | Buy Now | 60.31% | Stifel | Bradley Canino | → $37 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 77.64% | JP Morgan | Anupam Rama | → $41 | Initiates | → Overweight | Get Alert |
| 12/12/2022 | Buy Now | 68.98% | Goldman Sachs | Madhu Kumar | $35 → $39 | Maintains | Buy | Get Alert |
| 12/12/2022 | Buy Now | 42.98% | HC Wainwright & Co. | Edward White | $31 → $33 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 51.65% | Goldman Sachs | Madhu Kumar | $40 → $35 | Maintains | Buy | Get Alert |
| 07/28/2022 | Buy Now | 34.32% | B. Riley Securities | Kalpit Patel | → $31 | Reinstates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 73.31% | Goldman Sachs | Madhu Kumar | $51 → $40 | Maintains | Buy | Get Alert |
| 04/11/2022 | Buy Now | 34.32% | HC Wainwright & Co. | Edward White | → $31 | Initiates | → Buy | Get Alert |
| 02/15/2022 | Buy Now | 60.31% | Goldman Sachs | Madhu Kumar | → $37 | Initiates | → Buy | Get Alert |
| 10/12/2021 | Buy Now | -9.01% | Morgan Stanley | David Lebowitz | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Syndax Pharmaceuticals (SNDX) stock?
The latest price target for Syndax Pharmaceuticals (NASDAQ:SNDX) was reported by Jefferies on June 28, 2024. The analyst firm set a price target for $37.00 expecting SNDX to rise to within 12 months (a possible 60.31% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syndax Pharmaceuticals (SNDX)?
The latest analyst rating for Syndax Pharmaceuticals (NASDAQ:SNDX) was provided by Jefferies, and Syndax Pharmaceuticals initiated their buy rating.
When was the last upgrade for Syndax Pharmaceuticals (SNDX)?
There is no last upgrade for Syndax Pharmaceuticals
When was the last downgrade for Syndax Pharmaceuticals (SNDX)?
The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Syndax Pharmaceuticals (SNDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Syndax Pharmaceuticals (SNDX) correct?
While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a initiated with a price target of $0.00 to $37.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $23.08, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.